Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 8Terminated 2Withdrawn 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Recurrence 1Neoplasms 1Ependymoma 1Disease Progression 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interventional × marizomib × Clear all
NCT04341311 2024-02-15

DIPG

Dana-Farber Cancer Institute

Phase 1 Terminated
4 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Neoplasms, Recurrence

NCT03727841 2022-07-27

Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
4 enrolled 13 charts

Ependymoma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡